Barreleye, a Korean medical AI solutions startup, announced that it has secured approximately USD 10 million(KRW 14 billion) in strategic Series A funding from a global healthcare corporation. Barreleye had previously raised seed investments from Mirae Holdings and KAIC To Ventures.

The participating global healthcare company is a market-leading enterprise in medical imaging and diagnostics, and it plans to establish a strategic partnership with Barreleye for joint technology development and global market expansion.

Founded in 2021 by Professor Hyunmin Bae—Dean of the KAIST Startup Institute and faculty member in the School of Electrical Engineering—Barreleye is developing AI-driven diagnostic solutions that leverage deep learning and RF (radio-frequency) signal-based quantitative ultrasound analysis technologies. Its core technology enables high-resolution detection of microstructural changes within human organs.

The company is currently expanding its clinical applications across multiple areas, including breast cancer, thyroid disorders, liver diseases, and cardiovascular conditions, while actively conducting joint research with major hospitals in Korea and abroad as well as global medical device manufacturers.

Hyunmin Bae, CEO of Barreleye, commented, “This strategic investment validates the commercial-grade technological maturity of Barreleye’s ‘ultrasound-based AI diagnostic’ solutions in global clinical and industrial settings. We will work closely with our strategic partner to accelerate global clinical studies and regulatory approvals, paving the way for full-scale commercialization.”